tiprankstipranks
Advertisement
Advertisement

SEPN Stock Latest News

Septerna Initiated with Buy Rating on Advancing GPCR Pipeline, Strong Early Data and Novo Nordisk Partnership Support
RatingsSepterna Initiated with Buy Rating on Advancing GPCR Pipeline, Strong Early Data and Novo Nordisk Partnership Support
4d ago
SEPN
Septerna reports Q1 EPS (19c), consensus (27c)
PremiumThe Fly
Septerna reports Q1 EPS (19c), consensus (27c)
5d ago
SEPN
Septerna initiated with a Buy at Stifel
PremiumThe Fly
Septerna initiated with a Buy at Stifel
16d ago
SEPN
3 Best Tech Stocks to Buy this Week 04/15/26, According to Top Analysts
PremiumMarket News
3 Best Tech Stocks to Buy this Week 04/15/26, According to Top Analysts
1M ago
ALLT
CLBT
Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target
PremiumRatings
Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target
1M ago
SEPN
Septerna Begins Phase 1 Trial of Oral SEP-479
PremiumCompany AnnouncementsSepterna Begins Phase 1 Trial of Oral SEP-479
1M ago
8K
SEPN
Septerna doses first patients in SEP-479 trial
Premium
The Fly
Septerna doses first patients in SEP-479 trial
1M ago
SEPN
Septerna price target raised to $38 from $34 at JPMorgan
Premium
The Fly
Septerna price target raised to $38 from $34 at JPMorgan
2M ago
SEPN
Septerna, Inc. (SEPN) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Septerna, Inc. (SEPN) Q4 Earnings Cheat Sheet
2M ago
SEPN
Septerna price target raised to $35 from $34 at Truist
PremiumThe Fly
Septerna price target raised to $35 from $34 at Truist
2M ago
SEPN
Septerna files automatic mixed securities shelf
PremiumThe Fly
Septerna files automatic mixed securities shelf
2M ago
SEPN
Septerna: Novo-Backed GPCR Platform and Best-in-Class Potential for Oral MRGPRX2 Inhibitor SEP-631 Support Buy Rating
PremiumRatings
Septerna: Novo-Backed GPCR Platform and Best-in-Class Potential for Oral MRGPRX2 Inhibitor SEP-631 Support Buy Rating
2M ago
SEPN
Septerna reports Q4 EPS (24c), consensus (22c)
PremiumThe FlySepterna reports Q4 EPS (24c), consensus (22c)
2M ago
SEPN
Septerna (SEPN): Early Proof-of-Concept for SEP-631 in Mast Cell–Driven Disease Supports Long-Term Growth Potential
Premium
Ratings
Septerna (SEPN): Early Proof-of-Concept for SEP-631 in Mast Cell–Driven Disease Supports Long-Term Growth Potential
2M ago
SEPN
Septerna price target raised to $40 from $35 at H.C. Wainwright
Premium
The Fly
Septerna price target raised to $40 from $35 at H.C. Wainwright
2M ago
SEPN
Septerna Advances SEP-631 After Positive Phase 1 Results
PremiumCompany Announcements
Septerna Advances SEP-631 After Positive Phase 1 Results
2M ago
8K
SEPN
Septerna announces results from Phase 1 trial of SEP-631
PremiumThe Fly
Septerna announces results from Phase 1 trial of SEP-631
3M ago
SEPN
Septerna: Advancing GPCR Pipeline and De-Risked Valuation Support Upgraded Buy Rating and $35 Target
PremiumRatings
Septerna: Advancing GPCR Pipeline and De-Risked Valuation Support Upgraded Buy Rating and $35 Target
4M ago
SEPN
Septerna price target raised to $35 from $30 at H.C. Wainwright
PremiumThe Fly
Septerna price target raised to $35 from $30 at H.C. Wainwright
4M ago
SEPN
Septerna to Present GPCR Pipeline Updates at JPM Conference
PremiumCompany AnnouncementsSepterna to Present GPCR Pipeline Updates at JPM Conference
4M ago
8K
SEPN
Septerna Appoints Mark Wilson as Chief Legal Officer
Premium
Company Announcements
Septerna Appoints Mark Wilson as Chief Legal Officer
4M ago
8K
SEPN
Septerna appoints Mark Wilson as chief legal officer
Premium
The Fly
Septerna appoints Mark Wilson as chief legal officer
4M ago
NKTR
SEPN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >